[go: up one dir, main page]

MX2022016000A - COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) Y AGENTES DE QUIMIOTERAPIA. - Google Patents

COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) Y AGENTES DE QUIMIOTERAPIA.

Info

Publication number
MX2022016000A
MX2022016000A MX2022016000A MX2022016000A MX2022016000A MX 2022016000 A MX2022016000 A MX 2022016000A MX 2022016000 A MX2022016000 A MX 2022016000A MX 2022016000 A MX2022016000 A MX 2022016000A MX 2022016000 A MX2022016000 A MX 2022016000A
Authority
MX
Mexico
Prior art keywords
chemotherapy
hmb
methylbutyrate
hydroxy
compositions
Prior art date
Application number
MX2022016000A
Other languages
English (en)
Inventor
Lisa Pitchford
Felipe Karina Bettega
Eckert Dreher Raquel Goreti
Pedrosa Ronagela Curi
Original Assignee
Metabolic Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Tech Llc filed Critical Metabolic Tech Llc
Publication of MX2022016000A publication Critical patent/MX2022016000A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para administrar HMB a mamíferos que se someten al tratamiento de quimioterapia o que reciben un agente de quimioterapia para inhibir el crecimiento tumoral, incrementar la supervivencia animal, proteger contra la pérdida de peso inducida por la quimioterapia, proteger contra la inflamación inducida por la quimioterapia y/o proporcionar un tratamiento anti-caquéctico.
MX2022016000A 2020-06-15 2021-06-15 COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) Y AGENTES DE QUIMIOTERAPIA. MX2022016000A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038989P 2020-06-15 2020-06-15
PCT/US2021/037431 WO2021257562A1 (en) 2020-06-15 2021-06-15 COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) AND CHEMOTHERAPY AGENTS

Publications (1)

Publication Number Publication Date
MX2022016000A true MX2022016000A (es) 2023-06-15

Family

ID=79268309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016000A MX2022016000A (es) 2020-06-15 2021-06-15 COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) Y AGENTES DE QUIMIOTERAPIA.

Country Status (9)

Country Link
US (1) US20230263751A1 (es)
EP (1) EP4164623A4 (es)
JP (1) JP2023530336A (es)
KR (1) KR20230130600A (es)
CN (1) CN116685315A (es)
AU (1) AU2021292490A1 (es)
CA (1) CA3182874A1 (es)
MX (1) MX2022016000A (es)
WO (1) WO2021257562A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006331950A1 (en) * 2005-12-19 2007-07-05 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance of type 1 and type 2 cytokine production
ES2368963B1 (es) * 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
RU2019134551A (ru) * 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
JP2015209376A (ja) * 2014-04-24 2015-11-24 国立大学法人北海道大学 腫瘍特異的免疫増強剤
US11406609B2 (en) * 2016-01-21 2022-08-09 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
CA3011981C (en) * 2016-01-21 2024-01-16 Metabolic Technologies, Inc. Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) for modulating autophagy and lipophagy
CN109846029A (zh) * 2018-11-23 2019-06-07 广州欧普康特医食品有限公司 一种用于癌症患者的肠内营养剂

Also Published As

Publication number Publication date
CA3182874A1 (en) 2021-12-23
AU2021292490A1 (en) 2023-02-09
JP2023530336A (ja) 2023-07-14
EP4164623A1 (en) 2023-04-19
US20230263751A1 (en) 2023-08-24
KR20230130600A (ko) 2023-09-12
EP4164623A4 (en) 2024-07-10
WO2021257562A1 (en) 2021-12-23
CN116685315A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
MX2021015354A (es) Composiciones y metodos para administracion subcutanea de inmunoterapia de cancer.
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
BR112021011289A2 (pt) Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
PH12020551427A1 (en) Epinephrine spray formulations
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
GEP20257840B (en) Tyk2 pseudokinase ligands
PH12022550130A1 (en) Enzyme inhibitors
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
NZ758331A (en) B cells for in vivo delivery of therapeutic agents and dosages thereof
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
PH12021552866A1 (en) Compositions and methods for treating cancer
MX2020011817A (es) Metodos para tratar el linfoma.
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2024002069A (es) Anticuerpos anti-hla-g.
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
WO2020068950A8 (en) Hdac1,2 inhibitors
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.